Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair (Q41088379)

From Wikidata

Jump to navigation Jump to search

scientific article published on 20 June 2017

Language	Label	Description	Also known as
English	Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair	scientific article published on 20 June 2017

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

26 September 2017

Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair (English)

1 reference

Europe PubMed Central

PMC publication ID

26 September 2017

0 references

Irena Misiewicz-Krzeminska

7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28633670%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Jesús San Miguel

15

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28633670%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Norma C. Gutiérrez

17

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28633670%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Mercedes Garayoa

18

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28633670%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

19

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28633670%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Ana-Alicia López-Iglesias

1

object named as

Ana-Alicia López-Iglesias

1 reference

Europe PubMed Central

1 June 2020

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28633670%20AND%20SRC:MED&resulttype=core&format=json

PMC publication ID

Laura San-Segundo

4

object named as

Laura San-Segundo

1 reference

Europe PubMed Central

1 June 2020

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28633670%20AND%20SRC:MED&resulttype=core&format=json

PMC publication ID

11

object named as

Teresa Paíno

1 reference

Europe PubMed Central

1 June 2020

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28633670%20AND%20SRC:MED&resulttype=core&format=json

PMC publication ID

8

object named as

Dalia Quwaider

1 reference

Europe PubMed Central

1 June 2020

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28633670%20AND%20SRC:MED&resulttype=core&format=json

PMC publication ID

Lorena González-Méndez

5

object named as

Lorena González-Méndez

1 reference

Europe PubMed Central

1 June 2020

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28633670%20AND%20SRC:MED&resulttype=core&format=json

PMC publication ID

Montserrat Martín-Sánchez

9

object named as

Montserrat Martín-Sánchez

1 reference

Europe PubMed Central

1 June 2020

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28633670%20AND%20SRC:MED&resulttype=core&format=json

PMC publication ID

Susana Hernández-García

6

object named as

Susana Hernández-García

1 reference

Europe PubMed Central

1 June 2020

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28633670%20AND%20SRC:MED&resulttype=core&format=json

PMC publication ID

author name string

Ana B Herrero

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28633670%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Marta Chesi

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28633670%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Daniel Primo

10

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28633670%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

P Leif Bergsagel

12

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28633670%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Thomas Mehrling

13

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28633670%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Marcos González-Díaz

14

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28633670%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

María-Victoria Mateos

16

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28633670%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

publication date

20 June 2017

1 reference

Europe PubMed Central

PMC publication ID

26 September 2017

Journal of Hematology & Oncology

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28633670%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

10

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28633670%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28633670%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

127

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28633670%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Targeting Ongoing DNA Damage in Multiple Myeloma: Effects of DNA Damage Response Inhibitors on Plasma Cell Survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5477689

26 September 2017

Anti-tumor activity of the combination of bendamustine with vorinostat in diffuse large B-cell lymphoma cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5477689

26 September 2017

The Alkylating-HDAC Inhibition Fusion Principle: Taking Chemotherapy to the Next Level with the First in Class Molecule EDO-S101.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5477689

26 September 2017

Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: results of a prospective phase 2 Spanish/PETHEMA trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5477689

26 September 2017

Deregulation of DNA double-strand break repair in multiple myeloma: implications for genome stability

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5477689

26 September 2017

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5477689

26 September 2017

Phenotypic, genomic and functional characterization reveals no differences between CD138++ and CD138low subpopulations in multiple myeloma cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5477689

26 September 2017

Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5477689

26 September 2017

p53 haploinsufficiency and functional abnormalities in multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5477689

26 September 2017

OpenComet: an automated tool for comet assay image analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5477689

26 September 2017

New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5477689

26 September 2017

A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5477689

26 September 2017

Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5477689

26 September 2017

In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5477689

26 September 2017

Combination of bendamustine and entinostat synergistically inhibits proliferation of multiple myeloma cells via induction of apoptosis and DNA damage response

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5477689

26 September 2017

Suberoylanilide hydroxamic acid as a radiosensitizer through modulation of RAD51 protein and inhibition of homology-directed repair in multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5477689

26 September 2017

Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5477689

26 September 2017

Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5477689

26 September 2017

Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5477689

26 September 2017

The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5477689

26 September 2017

Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5477689

26 September 2017

Drug combination studies and their synergy quantification using the Chou-Talalay method

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5477689

26 September 2017

The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5477689

26 September 2017

Lysine acetylation targets protein complexes and co-regulates major cellular functions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5477689

26 September 2017

Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5477689

26 September 2017

Comparison of nonhomologous end joining and homologous recombination in human cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5477689

26 September 2017

A forward chemical genetic screen reveals an inhibitor of the Mre11-Rad50-Nbs1 complex

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5477689

26 September 2017

The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5477689

26 September 2017

Acetylation and deacetylation of non-histone proteins

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5477689

26 September 2017

Nuclear and mitochondrial conversations in cell death: PARP-1 and AIF signaling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5477689

26 September 2017

HDAC6 is a microtubule-associated deacetylase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5477689

26 September 2017

Histone deacetylases and cancer: causes and therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5477689

26 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5477689

26 September 2017

The acetylation of alpha-tubulin and its relationship to the assembly and disassembly of microtubules

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5477689

26 September 2017

Outcomes of primary refractory multiple myeloma and the impact of novel therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5477689

14 June 2018

Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5477689

14 June 2018

Pharmacological profiles of acute myeloid leukemia treatments in patient samples by automated flow cytometry: a bridge to individualized medicine.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5477689

19 August 2018

Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5477689

19 August 2018

Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5477689

19 August 2018

AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5477689

19 August 2018

Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and predniso

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5477689

19 August 2018

Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. IV. L-Phenylalanine mustard (NSC-8806)

1 reference

https://pubmed.ncbi.nlm.nih.gov/28633670

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/28633670

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The comet assay: a method to measure DNA damage in individual cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/28633670

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/S13045-017-0495-Y

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28633670%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28633670%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28633670%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41088379&oldid=2204264677"